Plexin B2 Tissue Expression and Gene Polymorphisms in Psoriasis
Study Overview
Psoriasis is a chronic skin disease with unclear causes. Plexin B2, found in the immune system, may be involved in psoriasis development. This study aimed to assess plexin-B2 tissue levels and related gene polymorphisms in psoriatic patients before and after NB-UVB, acitretin therapy alone or in combination. The goal was to detect any correlation between tissue plexin B2 levels and disease severity and improvement.
Key Findings
- A significant difference in tissue plexin-B2 levels was observed between control group and psoriatic patients.
- Tissue plexin-B2 levels were higher in severe psoriasis compared to moderate psoriasis.
- Tissue plexin B2 levels were positively correlated with disease severity.
- Higher occurrence of specific gene polymorphisms was found in psoriatic patients compared to healthy controls.
- Tissue plexin-b2 levels decreased after treatment, indicating a potential role in psoriasis pathogenesis.
Value of Clinical Trials
Clinical trials are crucial for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research, aiding clinicians in everyday medical practice. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and improving patient care.
By leveraging AI, clinics can enhance workflows, improve patient outcomes, and reduce paper-based routines. Learn more about our solutions at aidevmd.com.
